SEARCHNARRATIVE_REVIEWendocrinology, internal medicine

narrative_review·endocrinology, internal medicine, clinical trial, systematic review·PMC10821096

Novel Therapeutic Agents for Management of Diabetes Mellitus: A Hope for Drug Designing against Diabetes Mellitus

Life · 20 authors, 12 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This narrative review discusses novel therapeutic agents for diabetes mellitus that target multiple pathological mechanisms beyond just glycemic control. It concludes that while current drugs are being replaced by more potent options with fewer side effects, the search for better therapies, including phytomedicines, remains ongoing.

Full summary

557 CHARS

This is a narrative review of novel therapeutic agents for diabetes mellitus (DM). It outlines the complex pathogenesis of DM, including insulin resistance, impaired insulin secretion, and other factors. The review states that conventional therapies focus primarily on glycemic control, which can lead to treatment failure and side effects, driving the search for new drugs. It discusses the promise of novel interventions that target multiple pathogenic pathways and mentions the potential of phytomedicines due to their lower cost and side effect profile.

STUDY TYPE

narrative_review

SPECIALTY

endocrinology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10821096

Novel Therapeutic Agents for Management of Diabetes Mellitus: A Hope for Drug Designing against Diabetes Mellitus

Life

READ THE FULL PAPER

ABSTRACT

Diabetes mellitus (DM) is characterized by an absolute decline in insulin secretion and peripheral resistance and is the most prevalent metabolic and endocrine disorder. However, the pathogenesis of DM also includes adipocyte insulin resistance, increased glucagon secretion, increased renal glomerular glucose absorption, and neurotransmitter dysfunction. Although there is a wide spectrum of therapeutics available for glycemic control, owing to the identification of various pathogenic determinants of DM, management of DM remains challenging and complex. Current therapeutic interventions against DM focus mostly on glycemic control without considering the other pathological determinants that eventually lead to treatment failure and the progression of DM. Furthermore, long-term use of these conventionally available anti-diabetic drugs leads to various side effects, henceforth development of novel drugs against DM remains an unending search strategy for researchers. Various studies conducted in various parts of the world have proposed that these novel therapeutic interventions target multiple and alternate pathogenic hotspots involved in DM. The current review article discusses novel therapeutic options that hold particular promise to support their safety and discuss the side effects resulting from their use so that these novel candidate drugs can be effectively fabricated into potential drugs for the treatment of DM.

CITATION EXPORT

Ahmed M. E. Elkhalifa, Mehak Nazar, Sofi Imtiyaz Ali et al.. Novel Therapeutic Agents for Management of Diabetes Mellitus: A Hope for Drug Designing against Diabetes Mellitus. Life. (2024). https://doi.org/10.3390/life14010099

AUTHORS

20 · 12 CENTRES

Ahmed M. E. Elkhalifa, Mehak Nazar, Sofi Imtiyaz Ali, Ibraq Khursheed, Syed Taifa, Muzafar Ahmad Mir, Iqra Hussain Shah, Masood Malik, Zahid Ramzan, Shubeena Ahad, Nusrat Bashir, Elham Elamin, Elsharif A. Bazie, Elsadig Mohamed Ahmed, Majed Mowanes Alruwaili, Ammar W. Baltoyour, Abdullah Salah Alarfaj, Ibrahim Ali Al Bataj, Abdullah M. A. Arabe, Showkat Ul Nabi

1Department of Public Health, College of Health Sciences, Saudi Electronic University, Riyadh 11673, Saudi Arabia; [email protected]
2Department of Haematology, Faculty of Medical Laboratory Sciences, University of El Imam El Mahdi, Kosti 1158, Sudan; [email protected]
3Preclinical Research Laboratory, Department of Clinical Veterinary Medicine, Ethics & Jurisprudence, Sher-e-Kashmir University of Agricultural Sciences and Technology (SKUAST-Kashmir), Srinagar 190006, India; [email protected] (M.N.); [email protected] (S.I.A.); [email protected] (S.T.); [email protected] (M.A.M.); [email protected] (I.H.S.); [email protected] (M.M.); [email protected] (Z.R.); [email protected] (S.A.); [email protected] (N.B.)
4Department of Zoology, Central University of Kashmir, Nunar, Ganderbal 191201, India; [email protected]
5Pediatric Department, Faculty of Medicine, University of El Imam El Mahdi, Kosti 1158, Sudan; [email protected]
6Department of Clinical Chemistry, Faculty of Medical Laboratory Sciences, University of El Imam El Mahdi, Kosti 1158, Sudan
7Department of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, P.O. Box 551, Bisha 61922, Saudi Arabia
8Nursing Administration & Education Department, College of Nursing, Jouf University, Sakaka 72388, Saudi Arabia; [email protected]
9Dhahran Eye Specialist Hospital, Ministry of Health, Dhahran 39455, Saudi Arabia; [email protected]
10Dr. Suliman Al-Habib Hospital, Riyadh 11372, Saudi Arabia
11Najran General Hospital, Ministry of Health, Najran 66277, Saudi Arabia; [email protected]
12Diabetic Center and Unites, Ministry of Health, Riyadh 11176, Saudi Arabia

EDITOR / REVIEWER

Fabrizio Montecucco